UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
-------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): April 8, 2004
------------------------------
Immunomedics, Inc.
--------------------------------------------------------------------------------
(Exact Name of Registrant as Specified in Charter)
Delaware 000-12104 61-1009366
--------------------------------------------------------------------------------
(State or Other Jurisdiction (Commission (I.R.S. Employer
of Incorporation) File Number) Identification No.)
300 American Road, Morris Plains, New Jersey 07950
--------------------------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (973) 605-8200
--------------------------------------------------------------------------------
Not applicable
--------------------------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
ITEM 5. OTHER EVENTS AND REGULATION FD DISCLOSURE
On April 8, 2004, Immunomedics, Inc. and Amgen Inc. announced that
Amgen has returned to Immunomedics all rights for epratuzumab, the
humanized CD22 monoclonal antibody therapeutic licensed to Amgen by
Immunomedics in December 2000, including rights to second generation
molecules and conjugates. A copy of the press release announcing
this information is attached to this report as Exhibit 99.1 hereto
and is incorporated herein by reference.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS
(c) Exhibits:
99.1 Press Release issued by Immunomedics, Inc. and Amgen Inc.
on April 8, 2004.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned, hereunto duly authorized.
Date: April 8, 2004 IMMUNOMEDICS, INC.
By: /s/ Cynthia L. Sullivan
------------------------------------
Name: Cynthia L. Sullivan
Title: President and Chief Executive Officer
EXHIBIT INDEX
-------------
99.1 Press Release issued by Immunomedics, Inc. and Amgen Inc. on
April 8, 2004.